WSJ -- The Food and Drug Administration’s No. 2 official is leaving the agency after a busy 21-month tenure that included clashes with drug and device makers over tougher regulation.
WSJ -- The Food and Drug Administration’s No. 2 official is leaving the agency after a busy 21-month tenure that included clashes with drug and device makers over tougher regulation.
